Overview
At a Glance
Selank is a synthetic peptide based on the naturally occurring immunomodulatory peptide tuftsin, developed in Russia as an anxiolytic and nootropic. It is approved in Russia as an intranasal medication for anxiety and neurasthenia, with clinical data from Russian studies showing reduced anxiety without sedation. Western clinical data is very limited, and it is not approved by the FDA or EMA. It's available as a research peptide in most countries, with a generally favorable side-effect profile in the available literature.
Selank (also known as TP-7 or Selanc) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It is a modified analog of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of the heavy chain of immunoglobulin G (IgG). The Selank molecule extends tuftsin's sequence with a Pro-Gly-Pro tail (full sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro), which increases metabolic stability and prolongs the peptide's biological half-life (Kozlovskii & Danchev, 2003).
Selank was developed as a dual-action compound: an anxiolytic (anti-anxiety agent) with nootropic (cognitive-enhancing) properties. It modulates multiple neurotransmitter systems including GABA, serotonin, dopamine, and norepinephrine, producing anxiolytic effects without the sedation, cognitive impairment, or dependence associated with benzodiazepines. It was approved in Russia as an anxiolytic medication and has been used clinically in Russian medicine since the early 2000s (Seredenin & Kozlovskaya, 2012).
In addition to its neuropsychiatric applications, Selank retains the immunomodulatory properties of its parent molecule tuftsin. It has been shown to enhance innate immune function, modulate cytokine expression, and influence the activity of natural killer cells and monocytes. This dual anxiolytic-immunomodulatory profile is unusual among pharmaceutical compounds and reflects Selank's origins in immune system biology (Kozlovskii & Danchev, 2003).
The clinical evidence for Selank comes predominantly from Russian research institutions. While the published data includes controlled clinical trials, a significant limitation is the minimal independent replication of these findings by Western research groups. This creates an asymmetry in the evidence base: the Russian clinical literature is generally positive, but it has not been subjected to the same degree of independent verification that characterizes drugs approved by the FDA or EMA.
Quick Facts
| Property | Details |
|---|---|
| Molecular formula | C₃₃H₅₇N₁₁O₉ |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Molecular weight | ~751.9 Da |
| Parent molecule | Tuftsin (Thr-Lys-Pro-Arg) — an endogenous immunostimulatory peptide |
| Routes studied | Intranasal, subcutaneous injection, intraperitoneal (animal) |
| Clinical trials | Completed in Russia for generalized anxiety and cognitive impairment |
| Regulatory approval | Approved in Russia; not approved by FDA, EMA, or other Western agencies |
| Drug class | Anxiolytic / nootropic peptide |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
GABAergic Modulation
Selank enhances GABAergic neurotransmission — the primary inhibitory system in the central nervous system. Unlike benzodiazepines, which directly bind to and potentiate GABA-A receptors (causing sedation, amnesia, and dependence), Selank modulates the GABA system indirectly. It influences the expression and sensitivity of GABA receptors and alters the balance between excitatory and inhibitory neurotransmission without producing the characteristic benzodiazepine side effect profile (Seredenin & Kozlovskaya, 2012).
Electrophysiological studies have demonstrated that Selank alters GABA-A receptor subunit expression, particularly affecting the balance of α and γ subunits that determine receptor sensitivity and pharmacological response (Kasian et al., 2013).
Serotonergic System
Selank modulates serotonin (5-HT) metabolism, influencing the turnover and availability of serotonin in key brain regions associated with mood and anxiety regulation. Studies have shown that Selank increases serotonin metabolism in the hypothalamus and frontal cortex — regions critically involved in emotional processing and anxiety regulation. This serotonergic modulation contributes to its anxiolytic and potential antidepressant properties (Kozlovskii & Danchev, 2003).
Dopaminergic and Noradrenergic Effects
Selank influences dopamine and norepinephrine systems, which underlie its nootropic (cognitive-enhancing) properties. It has been shown to modulate dopamine turnover in the striatum and affect norepinephrine levels in the hippocampus — a region central to memory formation and retrieval. These effects are consistent with the observed improvements in attention, memory, and cognitive processing speed reported in clinical studies (Kozlovskii & Danchev, 2003).
BDNF and Neurotrophic Factors
Selank increases the expression of brain-derived neurotrophic factor (BDNF), a protein critical for neuronal survival, growth, and synaptic plasticity — the cellular basis of learning and memory. BDNF enhancement is a shared mechanism among several classes of antidepressants and cognitive enhancers. Selank's ability to increase BDNF expression may explain both its anxiolytic effects (BDNF deficiency is associated with anxiety and depression) and its nootropic properties (Seredenin & Kozlovskaya, 2012).
Enkephalin System
Selank inhibits enkephalin-degrading enzymes, leading to increased levels of endogenous enkephalins — the body's natural opioid peptides that modulate pain perception, stress response, and mood. By slowing the breakdown of enkephalins rather than directly activating opioid receptors, Selank enhances the body's natural stress-coping mechanisms without producing opioid-like effects or dependence (Kozlovskii & Danchev, 2003).
Immunomodulation (Tuftsin-Derived Activity)
Selank retains the immunomodulatory properties of tuftsin, its parent molecule. Tuftsin is a natural immune activator that stimulates phagocytosis (the engulfing and destruction of pathogens by immune cells). Selank has been shown to:
- Modulate cytokine expression, including IL-6, TNF-α, and IL-10
- Influence natural killer (NK) cell activity
- Enhance monocyte and macrophage phagocytic function
- Modulate the balance between pro-inflammatory and anti-inflammatory immune responses
This immune-modulating activity occurs at concentrations consistent with anxiolytic dosing, meaning both effects may operate simultaneously at standard doses (Kozlovskii & Danchev, 2003).
Go Deeper
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Research
Anxiety and Anxiolytic Effects
- Generalized anxiety disorder (clinical trial): A controlled clinical trial in patients with generalized anxiety disorder compared Selank (intranasal) to medazepam (a benzodiazepine). Selank produced comparable anxiolytic effects with fewer side effects — specifically, no sedation, cognitive impairment, or withdrawal symptoms observed with the benzodiazepine comparator (Kozlovskii & Danchev, 2003).
- Anxiety with neurasthenia: Clinical studies in patients with anxiety-neurotic disorders showed that Selank reduced anxiety scores (Hamilton Anxiety Rating Scale) with onset of effects within 1–3 days of treatment initiation (Seredenin & Kozlovskaya, 2012).
- Animal models of anxiety: Selank demonstrated anxiolytic activity in the elevated plus maze, light-dark box, and open field tests in rodents — standard behavioral models of anxiety. Effects were comparable to diazepam at equivalent anxiolytic doses, but without the motor impairment or sedation produced by diazepam (Kozlovskii & Danchev, 2003).
Cognitive Enhancement
- Memory and learning: Selank improved memory consolidation and retrieval in both animal models and human clinical studies. In a clinical trial involving patients with cognitive impairment associated with anxiety disorders, Selank improved attention, memory, and information processing speed. Effects on memory were measured using standardized neuropsychological batteries (Seredenin & Kozlovskaya, 2012).
- Conditioned avoidance: In animal models, Selank enhanced conditioned active avoidance learning and improved performance in maze navigation tasks, suggesting effects on both short-term and long-term memory formation (Kozlovskii & Danchev, 2003).
- BDNF enhancement: Selank increased BDNF expression in the hippocampus and frontal cortex of rodents — brain regions central to memory and executive function. BDNF enhancement is a well-established mechanism for cognitive improvement (Seredenin & Kozlovskaya, 2012).
Immune Modulation
- Cytokine regulation: Selank modulated the expression of multiple cytokines in immune cells, including upregulation of IL-10 (anti-inflammatory) and modulation of IL-6 and TNF-α. These effects were observed at doses consistent with anxiolytic use, suggesting dual neurological-immune activity (Kozlovskii & Danchev, 2003).
- Gene expression profiling: Microarray studies showed that Selank modulated the expression of 84 genes related to immune function, particularly those involved in chemokine signaling, inflammatory cytokine production, and T-cell differentiation (Kasian et al., 2013).
- Antiviral properties: Selank demonstrated antiviral activity in cellular models, potentially related to its modulation of interferon pathways and innate immune activation (Seredenin & Kozlovskaya, 2012).
Neuroprotection
- Oxidative stress protection: Selank reduced oxidative stress markers in brain tissue of animals subjected to chronic stress paradigms. It normalized lipid peroxidation and restored antioxidant enzyme levels in stressed animals (Kozlovskii & Danchev, 2003).
- Stress-induced neuronal damage: In chronic restraint stress models, Selank prevented stress-induced changes in hippocampal neuron morphology and preserved dendritic spine density — structural indicators of preserved cognitive function under chronic stress (Seredenin & Kozlovskaya, 2012).
Limitations of the Research
- Limited Western replication: The majority of clinical and preclinical research on Selank comes from Russian institutions. While the published data is methodologically reasonable, independent replication by Western research groups is minimal. This limits the confidence that can be placed in the findings by international standards.
- Publication access: Some Russian clinical trial data is published in Russian-language journals with limited international accessibility, making independent evaluation of the full evidence base difficult.
- No FDA-standard trials: No clinical trials meeting FDA standards for drug approval (multi-center, large sample sizes, rigorous blinding) have been conducted.
- Comparator limitations: Some clinical comparisons used older benzodiazepines rather than modern first-line anxiolytics (SSRIs, SNRIs), limiting the clinical relevance of comparison data.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
FDA Status
Selank has no FDA-approved indication. It is not classified as a drug, dietary supplement, or approved biologic in the United States. It is approved and prescribed in Russia for the treatment of generalized anxiety disorder and anxiety-asthenic conditions. Western use is off-label and experimental.
How It Has Been Accessed
- Compounding pharmacies: Selank has been available through licensed compounding pharmacies in the United States as a patient-specific preparation. With its return to Category 1 status, compounding access is expected to continue.
- Russian pharmaceutical market: Selank is commercially available in Russia as a nasal spray under its brand name, sold in pharmacies with a prescription.
- Research chemical suppliers: Available internationally as a research peptide, with the standard quality variability concerns of this market.
Common Clinical Applications
| Application | Evidence Basis | Notes |
|---|---|---|
| Generalized anxiety | Russian clinical trials | Primary approved indication in Russia. Used as an alternative to benzodiazepines for patients seeking anxiolysis without sedation, cognitive impairment, or dependence risk. |
| Cognitive enhancement | Russian clinical trials + preclinical | Used for attention, memory, and processing speed improvement, particularly in the context of anxiety-related cognitive impairment. |
| Stress resilience | Preclinical + clinical observation | Used to improve stress tolerance and adaptive capacity. Some providers use Selank as an adjunct during periods of high cognitive or emotional demand. |
| Immune support | Preclinical + mechanistic | Used for immune modulation based on tuftsin-derived immunomodulatory activity. Some providers combine Selank with other immune-supporting therapies. |
| Depression (adjunctive) | Limited clinical | Used as an adjunct to antidepressant therapy based on serotonergic and BDNF-enhancing properties. Not a standalone antidepressant treatment. |
What Selank Is NOT Used For
- Acute psychiatric crisis: Selank is not a fast-acting sedative or emergency anxiolytic. It does not have the immediate onset of benzodiazepines for acute panic or crisis situations.
- Psychosis or severe psychiatric illness: Selank has not been evaluated for schizophrenia, bipolar disorder, or other severe psychiatric conditions.
- Sleep aid: While Selank may improve sleep quality secondary to anxiety reduction, it is not a hypnotic and does not directly induce sleep.
- Pain management: Despite its effects on the enkephalin system, Selank is not an analgesic and should not be used for pain treatment.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
Selank is not FDA-approved. No FDA-standard dosing guidelines exist. The information below reflects protocols from Russian clinical practice and published research — it is provided for informational purposes only. Do not self-administer any peptide without guidance from a qualified healthcare provider.
Commonly Reported Protocols
| Route | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Intranasal spray | 200–400 mcg per administration | 2–3x daily | Primary route in Russian clinical practice. Nasal mucosa provides rapid absorption and CNS delivery. Typical concentration: 0.15% solution. |
| Subcutaneous injection | 250–500 mcg | 1–2x daily | Used by some providers for systemic delivery. Less clinical data than intranasal route. |
Dosing protocols above are derived from Russian clinical practice and published research — not from FDA-approved labeling. Key references: Seredenin & Kozlovskaya, 2012 · Kozlovskii & Danchev, 2003
Cycling Patterns
- Standard course (Russian protocol): 14 days of continuous use, followed by reassessment. Courses may be repeated after a 1–2 week break.
- Extended use: Some providers use Selank continuously for 4–8 weeks for chronic anxiety conditions, followed by a break.
- As-needed use: Some users employ Selank on an as-needed basis for acute stress situations, though the clinical data primarily supports course-based use.
- No dependence: Unlike benzodiazepines, Selank has not been associated with tolerance, dependence, or withdrawal in published clinical data. This suggests that strict cycling may be less critical than with GABAergic drugs, though periodic breaks are commonly recommended.
Intranasal Administration
The nasal spray route is preferred for several reasons:
- Direct access to the CNS via the olfactory and trigeminal nerve pathways
- Avoidance of first-pass hepatic metabolism (which destroys most peptides)
- Non-invasive administration
- Rapid onset of action (typically within 15–30 minutes)
Storage
- Nasal spray solution: Store refrigerated (2–8°C / 36–46°F). Use within the timeframe specified by the manufacturer or compounding pharmacy.
- Lyophilized powder: Store refrigerated. Stable for months when kept dry and cold.
- Reconstituted solution (injectable): Refrigerate and use within 2–4 weeks.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What Users Report
The timeline below is compiled from Russian clinical trial data, clinician reports, and user experiences. Independent Western clinical trial data is not available.
Reported Timeline
| Timepoint | What Users Typically Report |
|---|---|
| Day 1–3 | Reduction in baseline anxiety levels. Users describe feeling "calmer" or having a "quieter mind" without sedation. Some report improved stress tolerance during the first few days. |
| Week 1 | Anxiolytic effects become more consistent. Users report improved emotional regulation, reduced reactivity to stressors, and better sleep quality (secondary to anxiety reduction). Cognitive clarity may begin to improve. |
| Week 1–2 | Nootropic effects become apparent: improved focus, enhanced memory recall, and better sustained attention. Users describe a "sharpening" of cognitive function without stimulant-like side effects. |
| Week 2–4 | Full anxiolytic and cognitive effects established. Users report a stable baseline of reduced anxiety and improved cognitive performance. Immune function improvements may begin (though these are not typically subjectively perceived). |
| After discontinuation | Effects gradually diminish over 1–2 weeks. No withdrawal symptoms reported. Anxiety and cognitive function return to pre-treatment baseline gradually. |
Anxiolytic Reports
Users consistently describe Selank's anxiolytic effect as qualitatively different from benzodiazepines:
- Anxiety reduction without sedation — users remain alert and functional
- No cognitive "fog" or impairment — cognitive function is preserved or enhanced
- No euphoria or mood elevation — the effect is described as "calming" rather than "uplifting"
- No rebound anxiety upon discontinuation
- Maintained motivation and drive — unlike benzodiazepines, which can reduce initiative
Cognitive Reports
- Improved verbal fluency and word recall
- Enhanced ability to focus on complex tasks for sustained periods
- Better working memory during multitasking
- Improved information processing speed
- Some users report enhanced creative thinking and problem-solving
Limitations of Reported Results
- Subtle effects: Selank's effects are described as subtle — some users may not notice significant changes, particularly if expectations are calibrated to the more dramatic effects of benzodiazepines or stimulants.
- Placebo effect: Anxiety is particularly susceptible to placebo response. Without Western-standard blinded trials, the contribution of placebo effect is uncertain.
- Individual variability: Response appears to vary significantly between individuals, with some users reporting strong effects and others reporting minimal benefit.
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Fatigue | Uncommon | Mild tiredness reported by some users, typically during the first few days of use. Generally resolves with continued treatment. |
| Nasal irritation | Uncommon | Mild nasal discomfort, dryness, or irritation with intranasal administration. Related to the delivery route rather than the peptide itself. |
| Headache | Rare | Mild, transient headaches reported infrequently. |
| Dizziness | Rare | Occasional light-headedness, typically mild. |
| Altered taste/smell | Rare | Transient changes in taste or smell perception with intranasal use. |
| Injection site irritation | Rare | Mild redness at injection site with subcutaneous administration. |
Absence of Benzodiazepine-Type Side Effects
A key characteristic of Selank's side effect profile is the absence of effects commonly associated with benzodiazepines:
- No sedation: Selank does not impair alertness or cause drowsiness at therapeutic doses
- No cognitive impairment: Memory and attention are preserved or improved, not impaired
- No dependence: No physical dependence has been reported in clinical studies or post-marketing surveillance in Russia
- No tolerance: The anxiolytic effect does not diminish with continued use
- No withdrawal: Abrupt discontinuation does not produce withdrawal symptoms
- No motor impairment: Coordination and reaction time are not affected
Theoretical Risks and Concerns
- Long-term safety data: While Selank has been used clinically in Russia for over two decades, long-term safety data from Western-standard pharmacovigilance programs is not available.
- Immune modulation: Selank's immunomodulatory effects could theoretically interact with autoimmune conditions or immunosuppressive medications. Individuals with autoimmune disorders should consult their provider.
- Limited Western safety surveillance: Side effect data comes primarily from Russian clinical trials and post-marketing surveillance. The reporting standards and thoroughness may differ from FDA-standard pharmacovigilance.
Drug Interactions
No formal drug interaction studies meeting Western standards have been published. Theoretical interactions include:
- Benzodiazepines: Potential additive GABAergic effects. Monitor for excessive sedation if combined.
- SSRIs/SNRIs: Potential additive serotonergic effects. Theoretical risk of serotonin syndrome at high doses of both, though not reported.
- Immunosuppressants: Potential interference with immunosuppressive therapy due to immune-modulating effects.
- Other nootropics: May have additive or synergistic effects with other cognitive enhancers.
Contraindications
- Pregnancy and breastfeeding — insufficient safety data
- Known allergy to Selank or tuftsin
- Active autoimmune disease — consult provider regarding immune modulation
- Children — no pediatric data available
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
Russian Approval
Selank is approved by the Russian Ministry of Health as a registered pharmaceutical product for the treatment of anxiety disorders and anxiety-asthenic conditions. It is available by prescription in Russian pharmacies as a nasal spray formulation. This approval was based on clinical trials conducted within the Russian regulatory framework (Seredenin & Kozlovskaya, 2012).
United States Status
| Status | Details |
|---|---|
| FDA drug approval | None — no approved drug indication in the US |
| Compounding status | Returning to Category 1 (suitable for compounding) |
| Controlled substance | No — not a scheduled substance under the CSA |
| WADA status | Not specifically listed; may fall under S0 (non-approved substances) for athletes |
Category 1 Status
With its return to Category 1, Selank can be used as a bulk drug substance by licensed compounding pharmacies (503A and 503B) to prepare patient-specific formulations when prescribed by a licensed healthcare provider. This allows legal access through the established compounding pathway in the United States.
International Status
- Russia: Approved and commercially available as a prescription medication
- CIS countries: Available in some Commonwealth of Independent States countries following Russian regulatory recognition
- European Union: Not approved by the EMA; not available as a registered medication
- Rest of world: Generally not a controlled substance but not approved as a therapeutic agent outside of Russia and CIS
Research Chemical Market
Selank is available internationally through research chemical suppliers. The same quality and purity concerns that apply to all research peptides apply here. Products may vary in actual peptide content, purity, and stability. Certificate of analysis from third-party testing is recommended for any research-grade product.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Typical Pricing
| Source | Typical Price Range | What You Get | Quality Assurance |
|---|---|---|---|
| Compounding pharmacy (nasal spray) | $150–$250/month | Compounded nasal spray preparation, prescribed by provider. Standardized concentration and sterility. | Highest — regulated pharmacy, USP standards, prescription required. |
| Compounding pharmacy (injectable) | $150–$250/month | Lyophilized vial for subcutaneous injection, prescribed by provider. | Highest — regulated pharmacy, sterile preparation. |
| Research chemical supplier | $50–$120/month | Lyophilized powder, labeled "for research only." Buyer reconstitutes and prepares nasal spray or injectable solution. | Variable — some suppliers provide COAs; quality varies. |
| Russian pharmacy (import) | $30–$80/month | Commercially manufactured nasal spray (Russian pharmaceutical product). | Moderate to high — manufactured to Russian pharmaceutical standards, but import pathway introduces handling concerns. |
Insurance Coverage
Selank is not covered by any US insurance plan. It has no FDA-approved indication, and compounded peptide preparations are not eligible for insurance reimbursement. All costs are out-of-pocket.
Factors Affecting Cost
- Dosing frequency: Higher frequency (3x daily at 400 mcg) costs significantly more than lower frequency (2x daily at 200 mcg).
- Formulation: Pre-compounded nasal spray is more convenient but more expensive than self-prepared solutions from lyophilized powder.
- Source: Compounding pharmacies offer quality assurance at a premium; research suppliers offer lower prices with quality variability.
- Provider consultation: Initial consultations with providers specializing in peptide therapy range from $100–$300 in addition to product cost.
Cost Comparison: Selank vs. Related Treatments
| Treatment | Typical Monthly Cost | Insurance |
|---|---|---|
| Selank (compounding) | $150–$250 | Not covered |
| Selank (research chemical) | $50–$120 | Not covered |
| Generic SSRI (e.g., sertraline) | $4–$30 | Usually covered |
| Generic benzodiazepine | $4–$20 | Usually covered |
| Buspirone | $10–$40 | Usually covered |
| Cognitive behavioral therapy | $200–$800 (4 sessions) | Often partially covered |
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: Selank is just a placebo — Russian research can't be trusted.
Answer: This is an overgeneralization. Selank has published mechanistic data demonstrating specific effects on GABA receptor expression, serotonin metabolism, BDNF levels, and immune gene expression — objective biological endpoints that are not subject to placebo effect (Kozlovskii & Danchev, 2003; Kasian et al., 2013). The clinical trial data exists and shows consistent results. The legitimate concern is not that the research is fabricated, but that it lacks independent Western replication — which is a meaningful limitation but different from claiming the peptide is inert.
Myth: Selank works just like a benzodiazepine.
Answer: Selank produces anxiolytic effects but through fundamentally different mechanisms than benzodiazepines. Benzodiazepines directly potentiate GABA-A receptor activity, causing sedation, amnesia, motor impairment, and dependence. Selank modulates GABAergic neurotransmission indirectly while simultaneously affecting serotonin, dopamine, BDNF, and enkephalin systems. The clinical result is anxiety reduction without sedation, cognitive impairment, or dependence (Seredenin & Kozlovskaya, 2012). Users expecting a benzodiazepine-like experience may find Selank's effects too subtle.
Myth: Selank is addictive.
Answer: No dependence, tolerance, or withdrawal has been reported in published clinical data or post-marketing surveillance in Russia. This is consistent with its mechanism — it does not directly activate reward pathways or produce the euphoric effects associated with drugs of abuse. The Russian clinical experience over two decades of use has not identified addiction as a concern (Seredenin & Kozlovskaya, 2012).
Myth: Selank can replace my antidepressant or anti-anxiety medication.
Answer: Selank should not be used as a direct replacement for prescribed psychiatric medications without medical supervision. While it has anxiolytic properties, it has not been evaluated against modern first-line treatments (SSRIs, SNRIs) in Western-standard comparative trials. Abruptly stopping prescribed medications to switch to Selank could cause withdrawal effects from the discontinued medication and leave the underlying condition undertreated. Any medication changes should be managed by a prescribing clinician.
Myth: Intranasal peptides don't really reach the brain.
Answer: The intranasal route has well-established pharmacological evidence for CNS delivery. The nasal cavity provides direct access to the brain via olfactory nerve pathways and trigeminal nerve transport, bypassing the blood-brain barrier. Intranasal delivery of peptides, including insulin, oxytocin, and Selank, has been demonstrated to achieve CNS concentrations through this route. Selank's rapid onset of anxiolytic effects (within hours of intranasal administration) is consistent with direct CNS delivery (Kozlovskii & Danchev, 2003).
Myth: Selank boosts the immune system like a supplement.
Answer: Selank modulates immune function — it does not simply "boost" it. Its effects on cytokine expression involve both upregulation of anti-inflammatory mediators and modulation of pro-inflammatory signals. This is immunomodulation (rebalancing), not immunostimulation (unidirectional boosting). The distinction matters: immunomodulators can be beneficial in conditions of immune dysregulation, while indiscriminate immune "boosting" could worsen autoimmune conditions (Kasian et al., 2013).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide. It was developed in Russia as a dual anxiolytic-nootropic compound and has been approved for clinical use in Russia for over two decades.
- It produces anxiolytic effects without the side effects of benzodiazepines — no sedation, no cognitive impairment, no dependence, no tolerance, and no withdrawal. These characteristics are consistently reported in published clinical data.
- Nootropic effects include improved memory, attention, and processing speed, mediated through BDNF upregulation, serotonergic modulation, and dopaminergic/noradrenergic effects.
- The primary limitation is limited Western replication. While the Russian research base is internally consistent and demonstrates genuine pharmacological activity, independent validation by Western research groups is minimal. This gap is the single most important caveat for evaluating Selank's evidence base.
- It is not FDA-approved but is returning to Category 1 status for compounding pharmacy access in the United States.
- The safety profile appears favorable based on Russian clinical data and two decades of clinical use. Side effects are mild and infrequent.
- Cost ranges from $80–$250/month and is not covered by insurance.
- Selank also modulates immune function through its tuftsin-derived activity, affecting cytokine expression and innate immune cell activity at therapeutic doses.
Who Might Consider Selank
Based on the available evidence and clinical practice patterns, Selank may be worth discussing with a healthcare provider for individuals who:
- Experience generalized anxiety and seek an alternative to benzodiazepines (due to dependence concerns, sedation, or cognitive side effects)
- Want combined anxiolytic and cognitive enhancement effects
- Have not responded adequately to first-line anxiety treatments and are exploring adjunctive options
- Are interested in peptide-based approaches to anxiety management
- Understand the limitations of the evidence base (primarily Russian data, limited Western replication)
- Have access to a provider knowledgeable about peptide therapeutics
Questions to Ask a Provider
- Given my specific anxiety presentation, does the available evidence support trying Selank?
- Should I use intranasal or injectable administration?
- How does Selank fit with my current psychiatric medications, if any?
- What is the recommended course length, and how will we assess response?
- Where will the Selank be sourced, and what quality testing has been performed?
- What are the realistic expectations for improvement?
- Are there any interactions with my current medications or supplements?
- What should I try first — or is Selank an adjunct to existing treatment?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
Comprehensive Reviews
- Seredenin SB, Kozlovskaya MM (2012) — "Selank and its analogs: review of pharmacological properties and perspectives for clinical use" — Zhurnal Nevrologii i Psikhiatrii
- Kozlovskii II, Danchev ND (2003) — "The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats" — Neuroscience and Behavioral Physiology
Anxiety and Anxiolytic Effects
- Seredenin & Kozlovskaya (2012) — Clinical trial data for generalized anxiety
- Kozlovskii & Danchev (2003) — Anxiolytic efficacy in animal models
Cognitive Enhancement
- Seredenin & Kozlovskaya (2012) — Nootropic effects and BDNF
- Kozlovskii & Danchev (2003) — Memory and learning studies
Mechanism of Action
- Kasian A et al. (2013) — "Effect of Selank on the expression of genes encoding GABA-A receptor subunits and immune-related genes" — Bulletin of Experimental Biology and Medicine
- Kozlovskii & Danchev (2003) — Neurotransmitter modulation and enkephalin effects
- Seredenin & Kozlovskaya (2012) — BDNF and serotonergic mechanisms
Immune Modulation
- Kasian et al. (2013) — Immune gene expression profiling
- Kozlovskii & Danchev (2003) — Tuftsin-derived immunomodulatory activity
Regulatory & Classification
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
